Nuance Pharma announces dosing of first patient in the ENHANCE – China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.
Nuance Pharma announces dosing of first patient in the ENHANCE – China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.